effects upon the coagulant functions of FXa compared with anti-FXa IgG in patients with SLE without APS. FXa signalling has been observed in different cells, via activation of protease-activated receptors (PAR) which stimulates intracellular calcium (Ca 2þ ) release. Ca 2þ regulates many cellular processes and changes in its signalling may trigger several pathological changes. Given that cellular responses elicited through activation of PARs are important in influencing pathways responsible for inflammation, tissue repair and haemostasis, FXa-reactive IgG may be important in the pathogenesis of SLE and APS. Therefore, we characterized the interaction between FXa and human umbilical vein endothelial cells (HUVEC) and the cellular effects of anti-FXa IgG isolated from patients with APS and SLE without APS. Methods: IgG was purified from patients with APS (n ¼ 14) and SLE/no APS (n ¼ 14) who had anti-FXa IgG and healthy controls (HC) (n ¼ 8). The effect of IgGs on FXa-mediated intracellular calcium release was measured and quantified using the fluorescent image plate reader. HUVECs were seeded in 96-well plates, for 48 h and then incubated with Fluo-4AM calcium binding dye. Alterations in intracellular calcium release were monitored following stimulation with a-thrombin (Thr) or FXa AE IgGs. PAR inhibitors, agonist peptides (AP), HCQ, fluvastatin and desensitization experiments were also performed to characterize responses. Results: We observed a dose-dependent induction of Ca 2þ transients by FXa in HUVECS. FXa was a weaker agonist than Thr but the kinetics of response was different. APS IgG significantly potentiated the FXa-induced Ca 2þ release compared with SLE IgG (P ¼ 0.04), HC IgG (P < 0.05) and FXa alone (P < 0.05). FXa-mediated Ca 2þ release was significantly reduced by PAR-1 inhibitors. When PAR-1 receptors were desensitized by Thr and cells were stimulated by PAR-2 AP, PAR-2 response was reduced by 47.5%. When Thr-desensitized cells were stimulated by FXa, response was reduced by 66% and residual response was not inhibited by PAR-1 or completely by 2 inhibitors. IgG potentiation was lost on Thr-desensitized cells. When cells were treated with a specific FXa inhibitor, HCQ or fluvastatin, FXa induced and IgG potentiated intracellular Ca 2þ release was significantly reduced. Conclusion: FXa stimulation of HUVEC was mediated mainly via PAR1 and 2 dependent signalling mechanisms and this effect was enhanced by FXa-reactive APS-IgG. These effects were blocked by an FXa inhibitor which raises the exciting prospect that anti-FXa IgG positivity may be used as a novel biomarker to predict response to treatment with FXa inhibitors in APS. Despite the need for the specificity to be investigated further, results also suggest that HCQ and fluvastatin may be beneficial in patients with APS. Disclosure statement: The authors have declared no conflicts of interest. Background: Diffuse alveolar haemorrhage (DAH) is a rare and potentially fatal complication of the systemic vasculitides. DAH may present as a severe acute respiratory distress syndrome (ARDS) with reported mortality of 12-60%. Whilst a severe respiratory failure (SRF) strategy incorporating extracorporeal membrane oxygenation (ECMO) improves outcomes in ARDS, use of ECMO in DAH may be considered to be relatively contraindicated due to the requirement for systemic anticoagulation. Methods: A case series of four patients with DAH due to underlying ANCA-associated vasculitides diagnosed and/or managed by a standardized diagnostic pathway and ARDS treatment algorithm in a single, UK SRF centre, between 2012 and 2013. Analysis of the Extracorporeal Life Support Organisation (ELSO) database using ICD-9 codes 446.2, 446.21, 446.4, 446.6 to report the current international experience of DAH and ECMO. Results: Four patients with ARDS due to systemic vasculitides were referred via the SRF pathway, but only three patients required ECMO (range 120-208 h). Median lung injury score (LIS) was 3.5. 1 patient received a normal protocol heparin regime to target an APTTr of 1.5-2 while two patients had 48 h of ECMO with no heparin followed by subtherapeutic low-dose heparin. ICU survival and six months survival were 100% and there were no exacerbations of pulmonary haemorrhage, no new events of extra-pulmonary haemorrhage and no clotting complications ( Table 1 ). The ELSO database contains 78 patients (adult, 59; paediatric, 19) with pulmonary vasculitides who received ECMO. 43 had a diagnosis of granulomatosis with polyangiitis (GPA), whereas the remaining diagnoses included hypersensitivity angiitis, Goodpasture's syndrome and thrombotic microangiopathy. The median age was 23 years (IQR: 16-47). The median duration of ECMO was 190 h (IQR: 146-282) and ICU survival was 82%. Twelve patients (15%) were reported to have thrombotic ECMO circuit complications in the context of likely conservative heparinization. Conclusion: In this case series, ECMO offers an excellent survival rate and clinical outcomes in SRF due to ANCA-associated DAH. ELSO data supports our case series and suggests that DAH related to vasculitides should not be considered a contraindication. ECMO should be considered as supportive therapy in DAH patients with SRF not responsive to conventional therapy. Disclosure statement: The authors have declared no conflicts of interest.
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